# 2026-09448: FDA Surveys Teens on 'Real Cost' of Smoking Ads Impact

2026-09448, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-13, effective Submit written comments (including recommendations) on the collection of information by June 12, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09448
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09448
- Title: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 27062
- Published: 2026-05-13
- Effective: Submit written comments (including recommendations) on the collection of information by June 12, 2026.
- Comments close: 2026-06-12
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Surveys Teens on 'Real Cost' of Smoking Ads Impact

## Summary

The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- Longitudinal Youth Survey Recruiting: mixed, medium. FDA is extending the ExPECTT Cohort 3 study that surveys U.S. youth about tobacco. The study began in February 2023, targets youth ages 11-17 at baseline (with a supplemental social-media sample of ages 14-20), and includes a baseline plus up to eight follow-up surveys conducted about every 6-9 mon…
- Participant Time Burden and No Monetary Costs: cost, medium. FDA estimates the total respondent burden for the study extension at 59,799 hours. Individual study tasks include a youth survey of 0.50 hours (30 minutes) per response and household recruitment materials taking about 0.05 hours (9 minutes); FDA states there are no capital or operating and maintena…
- Parental Permission Waiver for 14+ Youth: benefit, low. FDA received an institutional review board waiver of parental permission for youth aged 14 and older, so parental permission is not required for those participants. Parental permission remains required for younger youth and for certain recruitment and recontact activities.
- Removal of Gender Identity Questions: mixed, low. To comply with Executive Order 14168, FDA will not assess or examine gender or gender identity in this study. The survey includes one sexual orientation item and one sex item: 'Are you female or male?'.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09448 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/13/2026-09448/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- [2026-09448 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09448.pdf)

## Related
- [Previous: 2026-09447, Center for Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2026-09447)
- [Next: 2026-09449, Agency Information Collection Activities; Submission to the Office of Managemen…](https://policyrisk.com/federal-register/2026-09449)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09448 (as of 2026-06-08).
